REMINDER: Our user survey closes on Friday, please submit your responses here.
I do think that PDSB will hit the $1B valuation, $25+, if the readouts continue to impress.
It is not just one drug but the whole platform that will come through.
That will add £20M+ to our valuation and take us over £2.00.
Add in the rest of the investments and 60p is just crazy. If Glycotest comes in you are looking at £3, £4 or £5 a share.
So far I have from the latest results and recent RNS.
Vortex £3M
SageTech £1M
QBot. £3M+
PDSB. £6.5M (@ $6.00)
DNAME. £1M
Cytrovale £1M
EMV. £5M (Premiums being paid everywhere for fund /asset managers)
Cash. £1M
Total £21.5M vs MCap of £14M
The ones above have real world values and are worth more than our Market Cap.
Glycotest is valued at another £11M in the books. Sale/fund raise before end of year.
Proaxis is valued at another £3M + in the books. Sale/fund raise before end of year.
Plus another 25 investments.
Insane value.
So far I have from the latest results and recent RNS.
Vortex £3M
SageTech £1M
QBot. £3M+
PDSB. £6.5M (@ $6.00)
DNAME. £1M
Cytrovale £1M
EMV. £5M (Premiums being paid everywhere for fund /asset managers)
Cash. £1M
Total £21.5M vs MCap of £14M
The ones above have real world values and are worth more than our Market Cap.
Glycotest is valued at another £11M in the books. Sale/fund raise before end of year.
Proaxis is valued at another £3M + in the books. Sale/fund raise before end of year.
Plus another 25 investments.
Insane value.
Nexxen and H/L Bridge Linear-to-Digital Gap for Local Advertisers
01/08/2023 2:00pm
GlobeNewswire Inc.
Tremor (NASDAQ:TRMR)
Intraday Stock Chart
Tuesday 1 August 2023
Click Here for more Tremor Charts.
Nexxen, a global, unified advertising technology platform with deep expertise in video and Connected TV ("CTV"), has joined forces with H/L, a renowned multiservice and independent agency that's been making momentum for local, regional and national marketers for nearly 40 years. The partnership empowers both local and national advertisers to operate marketing campaigns across digital and linear environments, leveraging Nexxen’s advanced data – including automatic content recognition (“ACR”) data from its exclusive relationship with VIDAA – and cross-channel technology to reach regional audiences.
Building on their successful collaboration with the Nexxen DSP (or demand-side platform, formerly known as Amobee), H/L began to explore and utilize the additional layers within Nexxen’s tech stack in 2022 – including the use of custom analytics, proximity to premium supply and proprietary data insights tools such as Nexxen Discovery (formerly Brand Intelligence). Now, H/L has matured its use of Nexxen’s offerings to bridge the gap between digital and linear campaigns for advertisers, specifically at the local level. By embracing the breadth of Nexxen’s platform, H/L and its advertising clients have successfully deployed cross-channel campaigns in an end-to-end fashion, thus elevating regional business growth and improving local measurement.
"Nexxen is the catalyst that brings together our creative development, traditional TV buying, programmatic and connected TV buying expertise,” said Jeremy Cobb, Vice President of Digital Platforms at H/L. “We seamlessly blend the art and science of advertising, creating a unified view that harnesses the power of targeting, tracking and optimization. In today's evolving advertising landscape, with CTV as the rising star, it's not just about the platform or inventory you choose. It's about delivering compelling messaging and ensuring its effective delivery that determines the success or failure of campaigns.”
Working with Nexxen, H/L enables its clients to analyze, plan, activate, measure and reinvest their marketing spend across media seamlessly — from linear to digital — through one holistic solution (rather than through multiple disparate partners), ultimately helping advertisers solve local video fragmentation. As a result, the agency is driving greater efficiency and savings for advertisers, eliminating the fees associated with working with multiple third-party entities.
"Our end-to-end platform is tailored to bring unparalleled support to our partners and their clients, both on a national and local level," said Kara Puccinelli, Chief Customer Officer at Nexxen. “As the digital and linear worlds converge, we are thrilled to partner with H/L, unleashing a con
An example of how keen the USA is to fund our sector.
Lynas Says U.S. Doubles Funding for Heavy Rare Earths Plant
01/08/2023 1:22am
Dow Jones News
Lynas Rare Earths (ASX:LYC)
Tuesday 1 August 2023
By Rhiannon Hoyle
Lynas Rare Earths said it has signed an updated contract with the U.S. Defense Department to build a heavy rare earths plant in Texas that includes a more-than doubled fiscal contribution from the government for the project.
Australia-listed Lynas said the U.S. government now intends to contribute roughly $258 million to the project, up from about $120 million in June 2022. The revised contract follows detailed design work and cost updates since the initial design was completed, Lynas said.
The company recently bought a large site in Seadrift, Texas, where it intends to develop both heavy and light rare earths separation plants.
"This further support by the DoD demonstrates the priority being given to developing robust and resilient rare earth supply chains," said Amanda Lacaze, the miner's chief executive
The Sunday Times reports that Rishi Sunak will announce funding for a multi-million pound carbon capture scheme in Aberdeenshire on Monday.
The paper says the project would allow greenhouse gas emissions to be stored under the North Sea while allowing oil and gas production to continue.
Some half decent buying of NSCI followed by a straight 10% rise of PDSB stock on no news!
Lots of old dogs having a bit of a run at the moment.
OPTI 6p to 42p. A massive red stain on my IG account that has finally gone.
Can't see any reason why we won't get a bit of the action with our 30+ investments all looking a little bit better every week.
Late trade of 455K shares on the Nas.
Wanda Health, the remote patient monitoring (RPM) solution for primary care patients, continues its commercial expansion in the US. The company is working towards securing regulatory position as an FDA-approved device, as well as achieving UKCA and CE Marks which allow for the platform to be sold in the UK and the EU respectively. The company which is dually based in the UK and US also continues development of AI modules and expansion of disease-monitoring programs. In the upcoming month, Wanda plans to launch a seed funding round to support its growth objectives.
Martlet Capital, the Cambridge based early-stage investor, participated in $7.5m Pre-Series A funding for PharmEnable, which has developed a proprietary drug discovery platform, and $2.1m investment round for RoboK, which uses AI to analyse security footage for incidents in real-time. EMV Capital is an investor in Martlet Capital and continues working with the Martlet team to identify scale-up opportunities for IP rich, high growth potential start-ups in the Cambridge ecosystem.
In December 2022, Deeptech Recycling Technologies, in which we hold a 30% direct stake, acquired the majority of assets of Recycling Technologies (a business that had targeted an AIM IPO in Q1 of 2022). EMV Capital’s value creation services team is working on a relaunch of the technology platform for upcycling post-consumer packaging with advanced, environmentally sound technologies company into the rapidly growing plastics waste management space.
EMV Capital syndicated new investment for NetScientific PLC portfolio company Glycotest, a liver disease diagnostics specialist based in Philadelphia, USA. The $1m third party fundraise is intended to provide Glycotest with further capital to progress development, prepare for market launch in the US, and explore wider market opportunities. Glycotest is pioneering the commercialisation of exclusive blood tests for the detection of life-threatening liver cancers and fibrosis-cirrhosis, which is well aligned with EMV Capital's practice and investments in the field of oncology.
EMV Capital led the completion of a £500,000 investment round in its genetic analysis portfolio company DName-iT, a KU Leuven spin-out, to accelerate further industry pilots, validating its technology and commercial strategy prior to product launch and commercial sales. DName-iT is looking to support the Laboratories industry, which is under increasing pressure to deliver accurate Next Generation Sequencing (NGS) testing for eligibility for novel oncology treatments and other critical advances in personalised medicine.
EpiBone, the first and only biotechnology company to gain FDA approval for human trials for a stemcell-based tissue product, has made significant progress in biphasic bone and cartilage graft development. The company has completed pivotal equine and canine studies, with very positive feedback from its preclinical work. EpiBone is now working towards IND approval for its osteochondral graft product, as well as the completion of clinical studies for its bone graft product.
ProAxis, the commercial medtech company with a focus on respiratory diagnostics, has secured a £500,000 funding facility from AB Group, advised by EMV Capital. ProAxsis has also started a collaboration with our portfolio company Wanda Health to deliver a digitally enabled COPD diagnostic platform.
Newsletter out.
EMV Capital led the completion of £3.2m investment round for Vortex Biosciences to support its next phase of growth in the multi-billion dollar oncology liquid biopsy market. Vortex is now undergoing a technical feasibility study using clinical samples to develop a reliable workflow for enumerating and characterising Circulating Tumour Cells with a US-based biospecimen CRO, MT Group. This will lead on to a clinical observational study that will help position Vortex with key biopharma customers.
Q-Bot, a leading UK robotics company in the building retrofit space, is experiencing significant revenue growth with a continuation of record-breaking months, driven by growing public and private sector market demand, operational efficiency, and improved robot reliability. The company's commercial development is progressing at pace with recent partners including the housing group Plus Dane Housing and Watford Borough Council. The company is actively working on expanding internationally in the EU and US through partnerships, including operations now in France and the Netherlands.
Sofant, the University of Edinburgh spin-out developing satellite and 5G antenna platforms, has announced a joint development with Inmarsat Government aimed at revolutionising the communication capabilities of aircraft. Sofant is currently building its first fully integrated satellite communications terminal, representing the most significant technical milestone in the company's history and a major value inflection point in the path to commercialisation. Designed to meet SES specifications, it will enable the company to achieve its second major milestone for the €7.2M European Space Agency contract.
Following its commercial launch in the UK, SageTech Medical, the sustainable anaesthesia provider, has achieved several significant commercial milestones, including distribution agreement with Dräger UK, Manchester University NHS Trust purchase and winning its first NHS Tender. The company's efficiency has also been confirmed by the internationally renowed Guy's and St Thomas' NHS Foundation Trust, concluding that its SID-Dock capture system has high baseline efficiency of 94.8%. The anaesthetic gas capture machine is now available through NHS Supply Chain.
VIDAA link from gadgie2 and Holgerbb reminded us that yet again the CFO held onto all his shares. 1M + now.
Love the VIDAA tie in let's hope we see a diff set of results Q2
https://advanced-television.com/2023/06/06/paramount-on-vidaa-in-latam-canada/
We are thrilled to partner with VIDAA to bring Paramount+ to millions of smart TV viewers in Canada and Latin America, including Brazil,” said Marco Nobili, Executive Vice President and International General Manager for Paramount+ ‘The deal is an incredible opportunity to get Paramount+ popular content, characters, and franchises available to an increasingly large audience, and a testament of our commitment to investing in customer choice”.
Wow. What a day of news!
I mentioned a while back that Tremor should go for Nielsen when they are finished with LG/Alphonso.
If you read the whole 150 page court case print out from last month? it was quite clear that LG had coerced (blackmailed) Nielson to do the dirty on Tremor.
To now have the Nielson deposition taken and added to the court case is a massive win for Tremor.
You now have Nielson spilling the beans and blaming everything on LG to save itself and the sacked team at Alphoso getting their own back on LG for being dumped.
There is not a chance in hell of LG taking this to court, especially with Burford capital advising.
Could not be happier.
Yup.
20k and 16k buys.
Also Ed Hooper has taken another 40K in shares rather than cash so another effective buy.
Lastly, the options are set at 63p which again is fair as they are only in the money when the SP goes up.
Onward and upward!
Loaf of Bread 1 Jul '23 - 13:51 - 5510 of 5512 Edit
My money is on a few more director buys.
loafofbread1 Jul '23 - 19:54 - 5511 of 5512 Edit
0 1 0
Market cap after Fridays announcement is approx £100M.
Glycotest is going for the liver test but same sized market.
The market values our Glycotest investment at zero but with (delayed)results by year end you can see what could happen.
Renalytix plc
("Renalytix" or the "Company")
FDA Approves KidneyIntelX.dkd(TM)
FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
LONDON and SALT LAKE CITY, June 30, 2023 - Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for its KidneyIntelX.dkd(TM) prognostic test. This affirms KidneyIntelX as a first-in-class, artificial intelligence enabled prognostic testing platform to guide care management for adults with type 2 diabetes and early-stage chronic (diabetic) kidney disease. Renalytix believes FDA authorization will lead to increasing test adoption, informing clinical guidelines, expanding insurance coverage, and pursuing additional international regulatory approvals.
" Meeting the rigorous safety, clinical and analytical validation, and scientific data requirements of an FDA review, from Breakthrough Device designation to De Novo marketing authorization, is a landmark event for health care providers and patients with diabetic kidney disease," said James McCullough, CEO of Renalytix. "With this approval, a new class, Prognostic Test for Assessment of Chronic Kidney Disease Progression, has been established by the FDA, providing a roadmap for future expansion of KidneyIntelX into new indications and products."
KidneyIntelX.dkd accurately stratifies patients into three risk levels (low, moderate, and high). This result provides comprehensive information on patient risk for progressive decline in kidney function within five years, independently of the current standard of care measures. KidneyIntelX.dkd is the name used to differentiate tests to be provided under the De Novo marketing authorization by the FDA from those provided under the KidneyIntelX name as a Laboratory Developed Test.
Since being introduced as a Laboratory Developed Test (LDT), KidneyIntelX results have been reported on approximately 10,000 patients in the United States and there has been broad insurance payment including from Medicare and many private payers.
The KidneyIntelX platform combines blood-based biomarkers with clinical variables using an artificial intelligence enabled algorithm, providing reliable and actionable information to guide care in large, at-risk patient populations. KidneyIntelX is based on technology developed at the Icahn School of Medicine at Mount Sinai in New York, NY, and licensed to Renalytix.
NSCI just added £2M to our asset value on a M Cap of £16M and no-one sees to have noticed.
SP should be up by 6p ffs.
Aim is totally fooked.
Hats off to the company for a very good deal.
Vortex £3M
SageTech £1M
QBot. £3M+
PDSB. £8M
Cash. £1M
The ones above have real world values and equal our Market Cap.
Glycotest is valued at £11M in the books. Even if it turns out to be worth zero by year end this company is seriously undervalued.